About Egalet (NASDAQ:EGLT)
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.
Industry, Sector and Symbol
Trailing P/E Ratio-0.349396187163907
Forward P/E Ratio-0.84
Sales & Book Value
Annual Sales$26.14 million
Price / Sales1.56
Price / CashN/A
Book Value$0.21 per share
Price / Book4.14
Return on EquityN/A
Return on Assets-64.43%
Egalet (NASDAQ:EGLT) Frequently Asked Questions
What is Egalet's stock symbol?
Egalet trades on the NASDAQ under the ticker symbol "EGLT."
How were Egalet's earnings last quarter?
Egalet (NASDAQ:EGLT) issued its earnings results on Monday, March, 12th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.11. The specialty pharmaceutical company earned $7.80 million during the quarter, compared to analyst estimates of $8.54 million. View Egalet's Earnings History.
When will Egalet make its next earnings announcement?
Where is Egalet's stock going? Where will Egalet's stock price be in 2018?
5 analysts have issued 1-year price targets for Egalet's stock. Their forecasts range from $1.50 to $9.50. On average, they expect Egalet's share price to reach $5.50 in the next year. View Analyst Ratings for Egalet.
Who are some of Egalet's key competitors?
Some companies that are related to Egalet include Xenon Pharmaceuticals (XENE), Alimera Sciences (ALIM), MEI Pharma (MEIP), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), Vascular Biogenics (VBLT), Brainstorm Cell Therapeutics (BCLI), Sophiris Bio (SPHS), Versartis (VSAR), Arcturus Therapeutics (ARCT), Aptevo Therapeutics (APVO), CytRx (CYTR), Novus Therapeutics (NVUS), Catabasis Pharmaceuticals (CATB), Caladrius Biosciences (CLBS), pSivida (PSDV), Cardiome Pharma (CRME) and PLx Pharma (PLXP).
Who are Egalet's key executives?
Egalet's management team includes the folowing people:
- Mr. Robert S. Radie, Pres, CEO & Director (Age 55)
- Dr. Mark Strobeck Ph.D., Chief Operating Officer and Exec. VP (Age 47)
- Mr. Patrick M. Shea, Chief Commercial Officer (Age 53)
- Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)
- Ms. Barbara A. Carlin, Chief Accounting Officer (Age 43)
Has Egalet been receiving favorable news coverage?
News headlines about EGLT stock have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Egalet earned a news sentiment score of 0.13 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 43.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are Egalet's major shareholders?
Egalet's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.57%). Company insiders that own Egalet stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Institutional Ownership Trends for Egalet.
Which major investors are buying Egalet stock?
How do I buy shares of Egalet?
Shares of EGLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Egalet's stock price today?
One share of EGLT stock can currently be purchased for approximately $0.87.
How big of a company is Egalet?
Egalet has a market capitalization of $41.47 million and generates $26.14 million in revenue each year. The specialty pharmaceutical company earns $-69,360,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Egalet employs 154 workers across the globe.
How can I contact Egalet?
Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected]
MarketBeat Community Rating for Egalet (EGLT)MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Egalet (NASDAQ:EGLT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.60||2.60||2.80||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$5.50||$6.20||$7.10||$7.10|
|Price Target Upside: ||532.18% upside||501.94% upside||602.97% upside||517.39% upside|
Egalet (NASDAQ:EGLT) Consensus Price Target History
Egalet (NASDAQ:EGLT) Analyst Ratings History
(Data available from 3/20/2016 forward)
Egalet (NASDAQ:EGLT) Earnings History and Estimates Chart
Egalet (NASDAQ EGLT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2018|| || || || || || || || |
|3/12/2018||n/a||($0.38)||($0.27)||$8.54 million||$7.80 million||View||Listen|
|11/8/2017||Q3 2017||($0.47)||($0.46)||$7.46 million||$6.65 million||View||N/A|
|8/9/2017||Q2 2017||($0.94)||($1.04)||$6.68 million||$6.26 million||View||Listen|
|5/10/2017||Q1 2017||($0.90)||($1.02)||$6.92 million||$5.57 million||View||N/A|
|3/9/2017||Q4 2016||($0.92)||($0.87)||$5.37 million||$6.14 million||View||Listen|
|11/4/2016||Q316||($0.90)||($1.10)||$4.50 million||$4.70 million||View||N/A|
|8/4/2016||Q216||($0.82)||($0.97)||$3.83 million||$3.45 million||View||N/A|
|5/10/2016||Q116||($0.87)||($0.76)||$3.50 million||$2.70 million||View||Listen|
|3/8/2016||Q415||($0.91)||($0.28)||$2.80 million||$2.10 million||View||N/A|
|11/4/2015||Q315||($0.90)||($0.81)||$1.62 million||$1.30 million||View||N/A|
|8/6/2015||Q215||($1.02)||($0.98)||$0.95 million||$0.96 million||View||N/A|
|5/7/2015||Q1 2015||($0.98)||($1.02)||$3.00 million||$0.81 million||View||N/A|
|3/16/2015||Q414||($0.71)||($0.52)||$0.30 million||$0.83 million||View||N/A|
Egalet (NASDAQ:EGLT) Earnings Estimates
Current Year EPS Consensus Estimate: $-1.03 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
Dividend History for Egalet (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by MarketBeat.com
Egalet (NASDAQ EGLT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 36.17%
Egalet (NASDAQ EGLT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/2/2018||Patrick M Shea||Insider||Sell||910||$1.00||$910.00||37,020|| |
|10/2/2017||Mark Strobeck||COO||Sell||8,700||$1.29||$11,223.00||12,080|| |
|10/2/2017||Patrick M Shea||Insider||Sell||910||$1.30||$1,183.00||37,930|| |
|7/3/2017||Patrick M. Shea||Insider||Sell||910||$2.35||$2,138.50|| |
|7/3/2017||Paul Varki||SVP||Sell||806||$2.35||$1,894.10|| |
|7/3/2017||Stan Musial||CFO||Sell||3,480||$2.36||$8,212.80||42,407|| |
|6/30/2017||Mark Strobeck||COO||Sell||8,700||$2.39||$20,793.00||20,780|| |
|4/3/2017||Paul Varki||SVP||Sell||806||$5.05||$4,070.30||28,820|| |
|4/3/2017||Stan Musial||CFO||Sell||8,613||$5.04||$43,409.52||45,887|| |
|3/31/2017||Jeffrey M Dayno||Insider||Sell||536||$5.16||$2,765.76||18,212|| |
|3/31/2017||Mark Strobeck||COO||Sell||8,700||$5.11||$44,457.00||29,480|| |
|3/20/2017||Patrick M Shea||Insider||Sell||4,250||$4.75||$20,187.50||38,250|| |
|1/3/2017||Jeffrey M Dayno||Insider||Sell||536||$7.75||$4,154.00||18,748|| |
|1/3/2017||Paul Varki||SVP||Sell||806||$7.75||$6,246.50||29,626|| |
|1/3/2017||Stan Musial||CFO||Sell||13,480||$7.73||$104,200.40||54,500|| |
|12/30/2016||Mark Strobeck||COO||Sell||8,700||$7.81||$67,947.00||38,180|| |
|10/3/2016||Paul Varki||SVP||Sell||806||$7.56||$6,093.36||30,432|| |
|10/3/2016||Robert S Radie||Insider||Sell||15,000||$7.47||$112,050.00||234,900|| |
|10/3/2016||Stan Musial||CFO||Sell||13,480||$7.47||$100,695.60||67,980|| |
|9/30/2016||Jeffrey M Dayno||Insider||Sell||536||$7.69||$4,121.84||19,284|| |
|9/30/2016||Mark Strobeck||COO||Sell||33,700||$7.58||$255,446.00||71,880|| |
|7/6/2016||Robert S Radie||CEO||Sell||15,000||$5.01||$75,150.00||259,900|| |
|7/5/2016||Robert S Radie||CEO||Sell||5,000||$4.94||$24,700.00||259,900|| |
|7/5/2016||Stan Musial||CFO||Sell||13,480||$5.06||$68,208.80||84,940|| |
|7/1/2016||Robert S Radie||CEO||Sell||5,000||$5.07||$25,350.00||259,900|| |
|7/1/2016||Stan Musial||CFO||Sell||10,000||$5.06||$50,600.00||84,940|| |
|6/30/2016||Jeffrey M Dayno||Insider||Sell||536||$4.65||$2,492.40||19,820|| |
|4/5/2016||Deanne F Melloy||Insider||Sell||860||$6.96||$5,985.60||33,420|| |
|4/5/2016||Robert S Radie||CEO||Sell||5,000||$6.99||$34,950.00||264,900|| |
|4/4/2016||Robert S Radie||CEO||Sell||10,000||$6.97||$69,700.00||274,900|| |
|1/11/2016||Robert S. Radie||CEO||Sell||10,000||$9.65||$96,500.00||279,900|| |
|1/6/2016||Robert S. Radie||CEO||Sell||5,000||$10.52||$52,600.00||298,900|| |
|10/6/2015||Deanne F Melloy||Insider||Sell||860||$11.42||$9,821.20||35,140|| |
|10/1/2015||Robert S Radie||CEO||Sell||15,000||$12.27||$184,050.00||303,900|| |
|10/1/2015||Stan Musial||CFO||Sell||8,480||$12.32||$104,473.60||101,900|| |
|9/30/2015||Mark Strobeck||Insider||Sell||5,220||$12.56||$65,563.20||106,680|| |
|7/8/2015||Robert S Radie||CEO||Sell||6,000||$11.97||$71,820.00|| |
|7/6/2015||Robert S Radie||CEO||Sell||9,000||$12.53||$112,770.00|| |
|7/1/2015||Mark Strobeck||Insider||Sell||10,440||$12.98||$135,511.20|| |
|7/1/2015||Stan Musial||CFO||Sell||8,480||$13.20||$111,936.00|| |
|4/1/2015||Robert S Radie||CEO||Sell||11,130||$11.25||$125,212.50|| |
|2/3/2015||Jeffrey M Dayno||Insider||Sell||2,500||$8.87||$22,175.00|| |
|1/2/2015||Mark Strobeck||Insider||Sell||3,480||$5.09||$17,713.20|| |
|1/2/2015||Robert S Radie||CEO||Sell||11,130||$5.11||$56,874.30|| |
|9/10/2014||Robert S Radie||CEO||Sell||40,040||$9.61||$384,784.40|| |
|9/8/2014||Robert S Radie||CEO||Sell||49,000||$9.74||$477,260.00|| |
|8/13/2014||Mark Strobeck||Insider||Sell||5,135||$9.20||$47,242.00|| |
|8/11/2014||Mark Strobeck||Insider||Sell||5,700||$10.28||$58,596.00|| |
|8/7/2014||Mark Strobeck||Insider||Sell||3,085||$11.50||$35,477.50|| |
|8/7/2014||Stan Musial||CFO||Sell||13,920||$11.05||$153,816.00|| |
|2/11/2014||Jean Francois Formela||Director||Buy||41,667||$12.00||$500,004.00|| |
|2/11/2014||Life Science Ventures Sunstone||Major Shareholder||Buy||133,333||$12.00||$1,599,996.00|| |
Egalet (NASDAQ EGLT) News Headlines
Egalet (NASDAQ:EGLT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Egalet (NASDAQ:EGLT) Income Statement, Balance Sheet and Cash Flow Statement
Egalet (NASDAQ EGLT) Stock Chart for Tuesday, March, 20, 2018